Finance entity
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.4.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.4. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) appears in 1 tracked Finance story from August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 44 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf). Shared-story counts are live from our verified record — not editorial picks.
Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
